FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216096981> ?p ?o ?g. }

• W3216096981 endingPage "4822" @default.
• W3216096981 startingPage "4822" @default.
• W3216096981 abstract "Abstract Background: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Despite the advancements in drug therapies, CLL is largely incurable, and relapsed/refractory (R/R) patients have a very poor prognosis. Chimeric antigen receptor T (CART) cell therapy has shown promising results in B-cell malignancies. We conducted a systematic review to assess the efficacy and safety of CART cell therapy in patients with CLL. Methods: PRISMA guidelines were followed to perform the literature search and selection of articles for this systematic review. A search was performed using databases including PubMed, Cochrane, Web of Science, Embase, and clinicaltrials.gov. We used the following Mesh and Emtree terms, Chronic lymphocytic leukemia AND Adoptive immunotherapy from the inception of literature till 06/11/2021. Out of 1319 articles, we screened and included nine clinical studies (N=208) measuring the efficacy (i.e., complete response, partial response, etc.) and safety (adverse events ≥grade 3) in clinical terms. We excluded case reports, pre-clinical studies, review articles, and meta-analyses. Results: In 9 clinical studies, 158 patients with CLL were treated with anti-CD19 CART cell therapy. The range of age of the patients was 38-75 years. A high dose was used in 38 patients, and ibrutinib was added in 19 patients with CLL. The therapy was well tolerated with ≥grade 3 cytokine release syndrome (CRS) and neurological toxicity reported in 23/151 (15%) and 20/151 (13%) of the patients, respectively. Table 1. Complete response (CR), partial response (PR), and overall response (OR) were seen in 40% (54/134), 17% (22/126), and 56% (103/183). In the clinical study by Frey et al. (N=51)., progression-free survival (PFS) and ORR were significantly higher in the high dose (5x10 8 cells/kg) group as compared to the low dose (5x10 7 cells/kg) group (1.8 months vs. one month and 53% vs. 29%, respectively) without significantly increasing treatment-related adverse events (TRAE). In the clinical study by Gauthier et al. (N=38)., ORR was significantly high in the anti-CD19 CART cell therapy + ibrutinib group compared to the no ibrutinib group (83% vs. 56%). Neutropenia, infection, thrombocytopenia, leukemia, hypocalcemia, elevated ALT, and tumor lysis syndrome were common ≥grade 3 TRAEs reported in these patients (Table 1). More clinical trials are targeting CD-20, CD-137, CD-7, CD-28, ROR1, etc (Table 2). Conclusion: Anti-CD19 CART cell therapy was safe and effective in the treatment of CLL patients. A high dose of 5x10 8/kg CART cell therapy was well tolerated and had superior efficacy. Adding ibrutinib to CART cell therapy was safe and more effective than anti-CD19 CART cell therapy alone. More placebo-controlled randomized multicenter studies are needed to confirm these results. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W3216096981 created "2021-12-06" @default.
• W3216096981 creator A5005067179 @default.
• W3216096981 creator A5006724902 @default.
• W3216096981 creator A5008235148 @default.
• W3216096981 creator A5008253905 @default.
• W3216096981 creator A5010730926 @default.
• W3216096981 creator A5011309513 @default.
• W3216096981 creator A5016846053 @default.
• W3216096981 creator A5021340476 @default.
• W3216096981 creator A5036372240 @default.
• W3216096981 creator A5066803984 @default.
• W3216096981 creator A5078739501 @default.
• W3216096981 creator A5080354924 @default.
• W3216096981 creator A5082623136 @default.
• W3216096981 creator A5084365894 @default.
• W3216096981 date "2021-11-05" @default.
• W3216096981 modified "2023-10-18" @default.
• W3216096981 title "Efficacy and Safety of Chimeric Antigen Receptor T Cell Therapy in Chronic Lymphocytic Leukemia: A Systematic Review" @default.
• W3216096981 doi "https://doi.org/10.1182/blood-2021-153595" @default.
• W3216096981 hasPublicationYear "2021" @default.
• W3216096981 type Work @default.
• W3216096981 sameAs 3216096981 @default.
• W3216096981 citedByCount "1" @default.
• W3216096981 countsByYear W32160969812022 @default.
• W3216096981 crossrefType "journal-article" @default.
• W3216096981 hasAuthorship W3216096981A5005067179 @default.
• W3216096981 hasAuthorship W3216096981A5006724902 @default.
• W3216096981 hasAuthorship W3216096981A5008235148 @default.
• W3216096981 hasAuthorship W3216096981A5008253905 @default.
• W3216096981 hasAuthorship W3216096981A5010730926 @default.
• W3216096981 hasAuthorship W3216096981A5011309513 @default.
• W3216096981 hasAuthorship W3216096981A5016846053 @default.
• W3216096981 hasAuthorship W3216096981A5021340476 @default.
• W3216096981 hasAuthorship W3216096981A5036372240 @default.
• W3216096981 hasAuthorship W3216096981A5066803984 @default.
• W3216096981 hasAuthorship W3216096981A5078739501 @default.
• W3216096981 hasAuthorship W3216096981A5080354924 @default.
• W3216096981 hasAuthorship W3216096981A5082623136 @default.
• W3216096981 hasAuthorship W3216096981A5084365894 @default.
• W3216096981 hasBestOaLocation W32160969811 @default.
• W3216096981 hasConcept C121608353 @default.
• W3216096981 hasConcept C126322002 @default.
• W3216096981 hasConcept C143998085 @default.
• W3216096981 hasConcept C17744445 @default.
• W3216096981 hasConcept C189708586 @default.
• W3216096981 hasConcept C197934379 @default.
• W3216096981 hasConcept C199539241 @default.
• W3216096981 hasConcept C203014093 @default.
• W3216096981 hasConcept C2777701055 @default.
• W3216096981 hasConcept C2777938653 @default.
• W3216096981 hasConcept C2778461978 @default.
• W3216096981 hasConcept C2779260929 @default.
• W3216096981 hasConcept C2779473830 @default.
• W3216096981 hasConcept C2779878957 @default.
• W3216096981 hasConcept C2780850621 @default.
• W3216096981 hasConcept C3875195 @default.
• W3216096981 hasConcept C71924100 @default.
• W3216096981 hasConceptScore W3216096981C121608353 @default.
• W3216096981 hasConceptScore W3216096981C126322002 @default.
• W3216096981 hasConceptScore W3216096981C143998085 @default.
• W3216096981 hasConceptScore W3216096981C17744445 @default.
• W3216096981 hasConceptScore W3216096981C189708586 @default.
• W3216096981 hasConceptScore W3216096981C197934379 @default.
• W3216096981 hasConceptScore W3216096981C199539241 @default.
• W3216096981 hasConceptScore W3216096981C203014093 @default.
• W3216096981 hasConceptScore W3216096981C2777701055 @default.
• W3216096981 hasConceptScore W3216096981C2777938653 @default.
• W3216096981 hasConceptScore W3216096981C2778461978 @default.
• W3216096981 hasConceptScore W3216096981C2779260929 @default.
• W3216096981 hasConceptScore W3216096981C2779473830 @default.
• W3216096981 hasConceptScore W3216096981C2779878957 @default.
• W3216096981 hasConceptScore W3216096981C2780850621 @default.
• W3216096981 hasConceptScore W3216096981C3875195 @default.
• W3216096981 hasConceptScore W3216096981C71924100 @default.
• W3216096981 hasIssue "Supplement 1" @default.
• W3216096981 hasLocation W32160969811 @default.
• W3216096981 hasOpenAccess W3216096981 @default.
• W3216096981 hasPrimaryLocation W32160969811 @default.
• W3216096981 hasRelatedWork W1996083006 @default.
• W3216096981 hasRelatedWork W1998208839 @default.
• W3216096981 hasRelatedWork W2151299033 @default.
• W3216096981 hasRelatedWork W2736687086 @default.
• W3216096981 hasRelatedWork W2900722963 @default.
• W3216096981 hasRelatedWork W2902590192 @default.
• W3216096981 hasRelatedWork W3119987272 @default.
• W3216096981 hasRelatedWork W3207614484 @default.
• W3216096981 hasRelatedWork W3213626125 @default.
• W3216096981 hasRelatedWork W3216096981 @default.
• W3216096981 hasVolume "138" @default.
• W3216096981 isParatext "false" @default.
• W3216096981 isRetracted "false" @default.
• W3216096981 magId "3216096981" @default.
• W3216096981 workType "article" @default.